Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29648809 | 1.00 | GABRA1 (0.47) | GABRA1GABRB2MEN1KMT2AGAA | |
| SCHEMBL326586 | 0.85 | GABRA1 (0.56) | GABRA1GABRB2MEN1KMT2ATDP1 | |
| SCHEMBL162206 | 0.85 | GABRA1 (0.50) | GABRA1GABRB2TDP1MAPK1CYP3A4 | |
| SCHEMBL158972 | 0.80 | GABRA1 (0.46) | GABRA1GABRB2MEN1KMT2AGAA | |
| SCHEMBL29812934 | 0.80 | GABRA1 (0.46) | GABRA1GABRB2MEN1KMT2AGAA | |
| SCHEMBL3635498 | 0.79 | GABRA1 (0.50) | GABRA1GABRB2MEN1KMT2ATDP1 | |
| SCHEMBL462306 | 0.78 | CYP3A4 (0.52) | GABRA1GABRB2MEN1KMT2ATDP1 | |
| SCHEMBL30625397 | 0.78 | CYP3A4 (0.52) | GABRA1GABRB2TDP1CYP3A4ALDH1A1 | |
| SCHEMBL9630070 | 0.78 | CYP3A4 (0.52) | GABRA1GABRB2TDP1CYP3A4ALDH1A1 | |
| SCHEMBL10614854 | 0.77 | GABRA1 (0.75) | GABRA1GABRB2TAAR1CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713378-A1 | ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS | Covestro Deutschland AG (DE) | 2026-03-25 | — | — | EP | disclosed |
| US-20250223263-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2025-07-10 | — | — | US | disclosed |
| US-12247011-B2 | Selective inhibitors of NLRP3 inflammasome | NodThera Limited (GB) | 2025-03-11 | — | — | US | disclosed |
| EP-3774961-B1 | ADDUCTS OF AMINE CATALYSTS FOR PRODUCING ISOCYANURATE POLYMERS | COVESTRO DEUTSCHLAND AG (DE) | 2025-01-15 | — | — | EP | disclosed |
| WO-2024236000-A1 | ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS | COVESTRO DEUTSCHLAND AG (DE) | 2024-11-21 | — | — | WO | disclosed |
| EP-4464727-A1 | ESTERIFIED ETHANOLAMINES FOR THE PREPARATION OF ISOCYANURATE POLYMERS | Covestro Deutschland AG (DE) | 2024-11-20 | — | — | EP | disclosed |
| US-20240150515-A1 | Low Viscosity Catalyst Compositions for Producing Isocyanurate Polymers | COVESTRO DEUTSCHLAND AG (DE) | 2024-05-09 | — | — | US | disclosed |
| EP-3543242-B1 | 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2024-01-03 | — | — | EP | disclosed |
| EP-4298140-A1 | LOW VISCOSITY CATALYST COMPOSITIONS FOR PRODUCING ISOCYANURATE POLYMERS | Covestro Deutschland AG (DE) | 2024-01-03 | — | — | EP | disclosed |
| CN-111356680-B | Selective inhibitors of NLRP3 inflammasome | 诺瑟拉有限公司 | 2023-11-28 | — | — | CN | disclosed |
| EP-2681221-B1 | TRICYCLIC INHIBITORS OF KINASES | ABBVIE INC (US) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015127041-A1 | A POLYISO-UREA | BASF SE (DE) | 2015-08-27 | — | — | WO | disclosed |
| WO-2015127038-A1 | POST-MODIFIED POLYCARBODIIMIDES | BASF SE (DE) | 2015-08-27 | — | — | WO | disclosed |
| US-8710065-B2 | Tricyclic inhibitors of kinases | ABBVIE INC. (US) | 2014-04-29 | — | — | US | disclosed |
| EP-2681221-A1 | TRICYCLIC INHIBITORS OF KINASES | AbbVie Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| US-8436004-B2 | Bicycloaniline derivative | MSD K.K. (JP) | 2013-05-07 | — | — | US | disclosed |
| WO-2012161812-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20120220572-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-08-30 | — | — | US | disclosed |
| US-20110135601-A1 | BICYCLOANILINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. | 2011-06-09 | — | — | US | disclosed |
| EP-2168966-A1 | BICYCLOANILINE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247011-B2 | Selective inhibitors of NLRP3 inflammasome | NLRP3, NOD1, NLRP1 | GABRA1 2922/4885GABRB2 2882/4885MEN1 2492/4885 |
| US-20250223263-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, NOD1, NLRP1 | GABRA1 2922/4885GABRB2 2882/4885MEN1 2492/4885 |
| US-20120220572-A1 | TRICYCLIC INHIBITORS OF KINASES | WEE1, WEE2, CDK1 | GABRA1 4519/4885GABRB2 4780/4885MEN1 1474/4885 |
| US-20110135601-A1 | BICYCLOANILINE DERIVATIVE | WEE1, WEE2, CCNK | GABRA1 4380/4885GABRB2 3786/4885MEN1 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.